[Form 4] enGene Therapeutics Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
enGene Therapeutics Inc. director and Interim Chief Medical Officer William Grossman reported receiving two stock option awards. He was granted options covering 200,000 common shares at an exercise price of $1.75 per share, vesting fully on the earlier of the first anniversary of a June 9, 2026 vesting commencement date or the company’s 2027 annual shareholder meeting, for his service as a non-executive director.
He was also granted options on 31,000 common shares at an exercise price of $1.75 per share, vesting in substantially equal monthly installments over 12 months, subject to his continued service as Interim Chief Medical Officer. Both awards expire on June 16, 2036 and are compensation grants rather than open-market purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Grossman William
Role
Interim Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 31,000 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 200,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 31,000 shares (Direct, null)
Footnotes (1)
- This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. These options were granted to the reporting person on June 16, 2026 for his service as a non-executive director, consistent with annual grants made to other non-executive directors of the board. This option vests monthly in substantially equal amounts on the 12th day of each month for 12 consecutive months, subject to the reporting person's continued service as Interim Chief Medical Officer at the time of each vesting. These options were granted to the reporting person in connection with his appointment as the Interim Chief Medical Officer of the Company.
Key Figures
Director option grant size: 200,000 shares
Executive option grant size: 31,000 shares
Exercise price: $1.75 per share
+3 more
6 metrics
Director option grant size
200,000 shares
Underlying common shares for non-executive director option grant
Executive option grant size
31,000 shares
Underlying common shares for Interim Chief Medical Officer option grant
Exercise price
$1.75 per share
Exercise price for both option grants
Director options post-grant
200,000 options
Total options following transaction for 200,000-share grant
Executive options post-grant
31,000 options
Total options following transaction for 31,000-share grant
Option expiration
June 16, 2036
Expiration date for both option awards
Key Terms
Stock Option (Right to Buy), vesting commencement date, exercise price, expiration date, +2 more
6 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
vesting commencement date financial
"the first anniversary of the vesting commencement date, which was June 9, 2026"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
exercise price financial
"conversion_or_exercise_price: 1.7500"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-06-16T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Interim Chief Medical Officer financial
"subject to the reporting person's continued service as Interim Chief Medical Officer"
non-executive director financial
"for his service as a non-executive director, consistent with annual grants"
A non-executive director is a member of a company’s board who does not work for the company day-to-day but provides independent oversight, strategic guidance and checks on management. For investors, they matter because they act like an impartial referee or outside advisor, helping ensure decisions protect shareholder interests, reduce risks of poor governance, and add credibility to financial reporting and long-term strategy.
FAQ
What insider transactions did enGene Therapeutics (ENGN) report for William Grossman?
William Grossman received two stock option grants. One covers 200,000 common shares and the other 31,000 shares, both at a $1.75 exercise price. These are compensation awards, not open-market purchases or sales, and relate to his director and Interim Chief Medical Officer roles.
What is the exercise price and expiration date of Grossman’s ENGN stock options?
Both option grants have an exercise price of $1.75 per common share and an expiration date of June 16, 2036. This means Grossman may choose to exercise vested portions any time before expiration, subject to the specific vesting conditions described in the awards.
Are Grossman’s ENGN option grants part of a routine compensation program?
Yes. The 200,000-share option was granted consistent with annual grants to other non-executive directors. The 31,000-share option was granted in connection with Grossman’s appointment as Interim Chief Medical Officer, reflecting standard equity-based compensation tied to board and executive responsibilities.